Laxibat 5 mg belongs to the generic category of Elobixibat. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Laxibat 5 mg. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Elobixibat and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

/ Piece
Laxibat 5 mg may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Laxibat 5 mg is provided below to help users gain a clear understanding of this medicine.
Elobixibat is indicated in chronic idiopathic constipation (except for constipation associated with organic diseases).
Elobixibat inhibits bile acid reabsorption via ileal bile acid transporter (IBAT) expressed on the epithelial cells of the terminal ileum and thereby increases the amount of bile acid passing into the large intestinal lumen. Bile acid promotes the secretion of water and electrolytes into the large intestinal lumen and enhances the colonic motility. Thus, induces the therapeutic effect on constipation.
The usual adult dose for oral use is 10 mg once daily as Elobixibat before meal. The dosage may be adjusted depending on the patient's symptoms but must not exceed the highest dose of 15 mg per day.Use in the elderly: Since the elderly generally have reduced physiological functions, cautions should be exercised, such as reducing the dose.Use in children: Safety has not been established in low-birth-weight infants, neonates, nursing infants, infants, or pediatric patients (no clinical experience).
Elobixibat should be administered with care when co-administered with the following drugs:Bile acid preparations, ursodeoxycholic acid, chenodeoxycholic acid: The inhibitory effect of Elobixibat on ileal bile acid transporter (IBAT) may interfere with reabsorption of bile acid preparations.Aluminum-containing antacids, sucralfate hydrate, aldioxa, etc: These drugs absorb bile acids in the gastrointestinal tract and may attenuate the effect of Elobixibat.Cholestyramine, colestimide: These drugs absorb bile acids and may attenuate the effect of Elobixibat.Digoxin, dabigatran etexilate methanesulfonate: Because of the inhibitory effect of Elobixibat on P-glycoprotein, the blood levels of these drugs may elevate and enhance their effectsMidazolam: The blood level of midazolam may decrease, and the effect of midazolam may decrease
Generally, Elobixibat is well tolerated in patients with chronic constipation. In clinical studies, the side effects include abdominal pain, diarrhea, nausea, abdominal discomfort, soft faeces, abdominal distension, liver function test abnormalities. If liver function test anomalies are detected, patient’s symptoms should be monitored carefully, if necessary, Elobixibat should be discontinued.
During Pregnancy: Should be used in pregnant women and women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.During Lactation: It is advised that lactating women should avoid Elobixibat. If treatment with Elobixibat is essential, breast feeding must be discontinued during treatment.
Precaution concerning indication: No clinical experience of use in drug-induced and disease-induced constipations. Precaution concerning dosage and administration: Elobixibat may cause abdominal pain or diarrhea; dose reduction, drug withdrawal, or discontinuation should be considered depending on the patient's symptoms. The need for continuing treatment with Elobixibat should be carefully evaluated on a regular basis to avoid continuing aimless administration.Careful administration: In patients with serious liver disorder, Elobixibat may fail to achieve its expected efficacy due to biliary obstruction or reduced bile acid secretion, etc.
Osmotic purgatives
Do not store above 25°C. Protect from light. Keep out of reach of children.
Data Source: Data source of Indications and Usages, Pharmacology, Dosage & Administration, Drug Interactions, Side Effects, Use during Pregnancy & Lactation, Precautions & Warnings, Use in Special Populations, Therapeutic Class, and Storage Conditions is the concerned medicine company or respective organization.
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

N:B-All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines"
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023